Medicines Substances Companies Statistics

A free, open platform for EU medicines data, based on official EMA data.

Database

Medicines
Substances
Companies

Data Sources

EMA

2026 uMedical - Open Source Project

Imprint
Privacy Policy
Terms
Contact

Xaluprine (previously Mercaptopurine Nova Laboratories)

Authorised

Human

Details

EMA number	EMEA/H/C/002022
ATC code	L01BB02
Authorisation	9 March 2012
Revision	19

Therapeutic indication

Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

MeSH: Leukemia, Lymphoid

Group: Antineoplastic agents

Active substances

6-mercaptopurine monohydrate

Marketing Authorisation Holder

Timeline

Filter by authority:

Xaluprine (previously Mercaptopurine Nova Laboratories) authorised

9 Mar 2012

authorisedregulatory

Xaluprine (previously Mercaptopurine Nova Laboratories) | uMedical